Article3 Biotech2025
Exploring the protective role of metformin and dehydrozingerone in sodium fluoride-induced neurotoxicity: evidence from prenatal rat models.
Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanistic Insights into metformin's neuroprotective effects against drug-induced neurotoxicity.Metabolic brain disease · 2026Review
- Senotherapeutics for Brain Aging Management.Neurology international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study is aimed at evaluating the neurotoxic effects of chronic exposure of sodium fluoride (NaF) in developmental stages in rat using prenatal models. NaF (100 ppm, orally) dosing via drinking water was given to pregnant rats in disease group. In the treatment groups, Metformin & Dehydrozingerone (DHZ) (200 mg/kg) were administered orally along with NaF, and the dosing was continued throughout the gestation and lactation periods to the pups until the end of experiment. Behavioural studies like Novel Object Recognition Test (NORT), Open Field & Actophotometer test and biochemical estimations like Acetylcholinesterase (AchE), Glutathione (GSH), Malondialdehyde (MDA) were conducted on animals followed by histopathological image analysis. It was observed that NaF exposure significantly decreased learning, memory and locomotor ability (at p < 0.05, p ≤ 0.01) in rat pups and was also able to induce anxiety like behavior. Levels of AchE (p ≤ 0.001) and MDA (p ≤ 0.01, p ≤ 0.001) was found to be significantly elevated and GSH levels were significantly decreased (p ≤ 0.01, p ≤ 0.001) in hippocampus and frontal cortex in the disease group. Histopathological image analysis showed presence of degenerated neurons in hippocampus of disease group. From this study, it was observed that treatment with Metformin and DHZ, was able to significantly ameliorate the cognitive impairments, improve the condition of oxidative stress and decrease neuronal degeneration in NaF fed rat pups. These results established the protective role of Metformin and DHZ in NaF induced neurodevelopmental toxicity with particular emphasis on their antioxidant properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.